Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

18.04 -0.62 (-3.32%)
Streaming Delayed Price Updated: 9:59 AM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Longboard Pharmaceuticals Inc

< Previous 1 2 Next >
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Longboard Pharmaceuticals, Inc.
Via Business Wire
This biotech stock has surged over 300% this week
Shares of Longboard Pharmaceuticals (NASDAQ: LBPH) have sky-rocketed higher this week, up over 300% thanks to breaking news 
Via MarketBeat
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives
From Longboard Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.